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Abstract
AIM: To evaluates the effectiveness and safety of the 
first generation, NS3/4A protease inhibitors (PIs) in 
clinical practice against chronic C virus, especially in 
patients with advanced fibrosis. 
METHODS: Prospective study and non-experimental 
analysis of a multicentre cohort of 38 Spanish hospitals 
that includes patients with chronic hepatitis C genotype 
1, treatment-naïve (TN) or treatment-experienced (TE), 
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who underwent triple therapy with the first generation 
NS3/4A protease inhibitors, boceprevir (BOC) and 
telaprevir (TVR), in combination with pegylated 
interferon and ribavirin. The patients were treatment in 
routine practice settings. Data on the study population 
and on adverse clinical and virologic effects were 
compiled during the treatment period and during follow 
up.
RESULTS: One thousand and fifty seven patients were 
included, 405 (38%) were treated with BOC and 652 
(62%) with TVR. Of this total, 30% (n  = 319) were TN 
and the remaining were TE: 28% (n  = 298) relapsers, 
12% (n  = 123) partial responders (PR), 25% (n  = 260) 
null-responders (NR) and for 5% (n  = 57) with prior 
response unknown. The rate of sustained virologic 
response (SVR) by intention-to-treatment (ITT) was 
greater in those treated with TVR (65%) than in those 
treated with BOC (52%) (P  < 0.0001), whereas by 
modified intention-to-treatment (mITT) no were found 
significant differences. By degree of fibrosis, 56% 
of patients were F4 and the highest SVR rates were 
recorded in the non-F4 patients, both TN and TE. In the 
analysis by groups, the TN patients treated with TVR 
by ITT showed a higher SVR (P  = 0.005). However, by 
mITT there were no significant differences between 
BOC and TVR. In the multivariate analysis by mITT, 
the significant SVR factors were relapsers, IL28B CC 
and non-F4; the type of treatment (BOC or TVR) was 
not significant. The lowest SVR values were presented 
by the F4-NR patients, treated with BOC (46%) or 
with TVR (45%). 28% of the patients interrupted the 
treatment, mainly by non-viral response (51%): this 
outcome was more frequent in the TE than in the TN 
patients (57% vs  40%, P  = 0.01). With respect to 
severe haematological disorders, neutropaenia was 
more likely to affect the patients treated with BOC 
(33% vs  20%, P  ≤ 0.0001), and thrombocytopaenia 
and anaemia, the F4 patients (P  = 0.000, P  = 0.025, 
respectively). 
CONCLUSION: In a real clinical practice setting with 
a high proportion of patients with advanced fibrosis, 
effectiveness of first-generation PIs was high except for 
NR patients, with similar SVR rates being achieved by 
BOC and TVR.
Key words: Hepatitis C; Boceprevir; Telaprevir; First-
generation protease inhibitors; Advanced fibrosis
© The Author(s) 2015. Published by Baishideng Publishing 
Group Inc. All rights reserved.
Core tip: To the best of our knowledge, this study 
objectively evaluates the effectiveness and safety of 
first-generation protease inhibitors in routine clinical 
practice against chronic C virus infection. A total of 
1057 patients with chronic hepatitis C genotype 1, 
treatment with triple therapy (boceprevir or telaprevir 
in combination with peginterferon and ribavirin) were 
included: 30% (n  = 319) were treatment-naïve and 
one serious adverse effect[10-12].
In Spain, this approach has mainly been used 
to treat patients presenting a high degree of liver 
fibrosis, in accordance with Ministry of Health re-
commendations[13], in the view that this population 
is a more complex one, with more comorbidities 
than HCV patients detected at earlier stages of the 
disease[7,8,14,15]. The aim of the present study is to 
evaluate the efficacy and safety of triple therapy 
with first-generation PIs in clinical practice, both in 
treatment-naïve patients (TN) and in treatment-
experienced ones (TE).
MATERIALS AND METHODS
Patients
A total of 1057 Spanish patients have been included in 
the national Register of Patients with Chronic Hepatitis 
C treated with PIs, administered by the Andalusian 
Public Health and Progress Foundation (protocol 
code FSE-TEL-2013-01), designed in compliance with 
applicable national legislation (Act 15/1999 LOPD and 
the Biomedical Research Act 14/2007). All patients 
involved in the study were informed verbally and in 
writing of the characteristics of the study obtaining 
their consent to participate by signing the informed 
consent (in accordance with the Declaration of 
Helsinki). This study was approved of the Andalusian 
Coordinating Committee for Biomedical Research 
Ethics, the Ethics Committees of each of the 38 
hospitals that have contributed to the Register and 
Spanish Agency of Medicines and Health Product. 
The present study is an open, prospective, non-
experimental analysis of a multicentre cohort including 
patients with HCV genotype 1, both TN and TE, who 
meet the requirements, according to rules set out 
by the Health Ministry and by each Autonomous 
Community, to be treated with first-generation PIs, 
BOC or TVR, i.e., these patients all present moderate 
or advanced liver fibrosis (Metavir fibrosis score of F3 
or F4). The diagnosis of liver fibrosis was established 
according to local clinical practice. For most patients, 
Fibroscan was used according to the manufacturer’s 
instructions (Fibroscan, Echosens). The results were 
expressed in kilopascals (kPa) applying the following 
cut-off values to determine the degree of fibrosis[16]: 
< 7.5 kPa, mild or no fibrosis (F0-F1); ≥ 7.5 kPa 
and < 9.5 kPa, significant fibrosis (F2); ≥ 9.5 kPa 
and < 12.5 kPa, severe fibrosis (F3); ≥ 12.5 kPa, 
liver cirrhosis (F4). All patients in the study, and 
in accordance with applicable national legislation, 
gave their informed consent to be included in the 
Register. The following exclusion criteria were applied: 
simultaneous participation in another research study, 
non-availability to follow up, contraindications for triple 
therapy, coinfection with HBV and/or HIV, advanced 
liver cirrhosis and liver transplantation.
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the remaining 738 (70%) were treatment-experienced: 
28% were relapsers, 12% were partial responders, 
25% were null-responders and for 5% the prior 
response was unknown. At present not all patients 
can be treated with new molecules as simeprevir or 
sofosbuvir. 
Salmerón J, Vinaixa C, Berenguer R, Pascasio JM, Sánchez 
Ruano JJ, Serra MÁ, Gila A, Diago M, Romero-Gómez M, 
Navarro JM, Testillano M, Fernández C, Espinosa D, Carmona 
I, Pons JA, Jorquera F, Rodriguez FJ, Pérez R, Montero JL, 
Granados R, Fernández M, Martín AB, Muñoz de Rueda P, 
Quiles R; Alhambra Spanish Study Group. Effectiveness and 
safety of first-generation protease inhibitors in clinical practice: 
Hepatitis C virus patients with advanced fibrosis. World J 
Gastroenterol 2015; 21(30): 9163-9174  Available from: URL: 
http://www.wjgnet.com/1007-9327/full/v21/i30/9163.htm  DOI: 
http://dx.doi.org/10.3748/wjg.v21.i30.9163
INTRODUCTION
The hepatitis C virus (HCV) is a global health problem. 
Estimates suggest that in 2005 about 185 million 
people worldwide were infected with HCV and that 
the prevalence had increased by 2.3% with respect to 
1990[1]. Moreover, about 80% of patients progress to 
chronicity, and between 5%-30% to liver cirrhosis and 
hepatocellular carcinoma[2], which provoke 366000 
deaths annually[3].
For decades, the standard treatment for chronic 
hepatitis C (CHC) has been based on a combination 
of pegylated interferon (PEG-IFN) and ribavirin (RBV), 
which achieve a rate of sustained virologic response 
(SVR) of 41%[4,5]. However, a few years ago, direct-
acting antiviral agents (DAAs) such as boceprevir 
(BOC) and telaprevir (TVR), which are first-generation 
NS3/4A protease inhibitors (PIs), were incorporated 
into treatment protocols. With the use of these PIs, the 
rate of SVR has increased in clinical phase ? trials by 
up to 75% in HCV genotype 1 patients, although the 
treatment is complicated by problems of tolerability 
and other adverse effects. However, to date most 
clinical trials have not accurately reflected the patients 
being treated in clinical practice, because the study 
population tends to be composed of carefully selected 
subjects, with very few cirrhotic patients being 
included[6-9]. For this reason, some studies conducted 
to examine the efficacy and safety of triple therapy in 
patients with advanced liver disease, such as those 
examining the CUPIC cohort in the French Early 
Access programme and the American Veterans cohort, 
have concluded that despite achieving high levels of 
SVR, PIs are associated with a higher rate of adverse 
events, including deaths, cirrhotic decompensation, 
dermatologic disorders and severe anaemias, with 
51%-54% of the patients treated presenting at least 
Salmerón J et al . Effectiveness of PIs in patients F4 CHC
nonparametric test. The response to antiviral therapy 
was tested using binary logistic regression with 
bivariate and multivariate analysis, together with the 
propensity score. In nonrandomized studies treatment 
selection is often influenced by subject characteristics. 
Thus, in our case, the baseline characteristics of 
the subjects may differ depending on the treatment 
used. Therefore, one must account for systematic 
differences in baseline characteristics between different 
treatments when estimating the effect of treatment on 
outcomes. Therefore, one must account for systematic 
differences in baseline characteristics between different 
treatments when estimating the effect of treatment 
on outcomes. For this reason, we used methods 
based on the propensity score to reduce or eliminate 
confounding effects when using observational 
data[17,18]. Thus, in a set of subjects, all of whom have 
the same propensity score, the distribution of the 
observed baseline covariates will be the same between 
the two treatment groups. To adjust the regression, we 
incorporated a large set of background covariates to 
estimate the propensity score and then used a subset 
of these covariates (previous response, IL28B, fibrosis, 
treatment, logarithm GGT and logarithm viral load) 
and the propensity score in the regression adjustment. 
The criterion for statistical significance was P ≤ 0.05. 
Data management and analysis were performed using 
SPSS 15.0 for Windows.
The statistical methods of this study were reviewed 
by Paloma Muñoz de Rueda from San Cecilio University 
Hospital
RESULTS
A total of 1057 patients with CHC participated in this 
study. 405 (38%) were treated with BOC and 652 
(62%) with TVR (Table 1). Of the 1057 patients, 30% 
(n = 319) were TN and the rest were TE. 34% of the 
patients treated with TVR were relapsers (R), vs 19% 
of those treated with BOC (P ≤ 0.0001). 958 patients 
were tested for liver fibrosis (Table 1), and 33% of the 
non-F4 patients were found to be R (compared to 24% 
of the F4 patients), while 28% of the F4 patients were 
null responders (NR) (vs 20% of the non-F4 patients, 
P = 0.01) (Table 1).
The baseline characteristics of all patients and 
those according to prior response are shown in Table 2. 
In the total patients, there were significant differences 
between BOC and TVR in liver fibrosis (P = 0.002), 
GGT (P = 0.05) and albumin (P = 0.04); in the TN 
patients, in liver fibrosis (P = 0.000); in the R patients, 
in albumin (P = 0.03); in the partial responders (PR) 
patients, in liver fibrosis (P = 0.03) and in albumin (P 
= 0.02) and, finally, in the NR patients, in GGT (P = 
0.04).
The SVR results (Figure 2) were obtained by 
grouping the patients by ITT (n = 1057) (Figure 2A) 
and by mITT (n = 952) (Figure 2B). In the group 
Data compilation and processing
Treatment was prescribed according to the recom-
mendations of product characteristics for each of the 
drugs used. Data were compiled by the specialist 
in question during the treatment and follow-up. 
The minimum set of common data was obtained 
using data collection protocols, taking into account 
sociodemographic, diagnostic, clinical, treatment and 
analytical variables.
RNA-HCV monitoring
The viral load, or level of HCV RNA, was determined, 
following the recommendations of standard clinical 
practice, at the following times: baseline, at weeks 
4, 12, 24 and 48 wk of treatment and at 12 wk post-
treatment. HCV-RNA was determined in serum with 
the Amplicor HCV Kit (Roche Diagnostics System). 
HCV-RNA serum levels were validated real-time PCR-
based assays COBAS AmpliPrep/COBAS TaqMan (Roche 
Molecular Systems, Pleasanton, CA, United States) 
with a lower limit of detection of 15 IU/mL. Testing was 
performed at each site, following local practice.
Effectiveness and safety
Treatment effectiveness, i.e., the likelihood of achieving 
SVR at 12 wk post-treatment, was assessed by 
intention to treatment (ITT), including all patients 
(n = 1057), and by modified intention to treatment 
(mITT; n = 952), excluding patients who had a 
decrease of less than 1log10 IU per millilitre in the 
HCV RNA level during the 4-wk lead-in period and had 
not received any dose of BOC or TVR (Figure 1). The 
adverse effects reported by patients were compiled 
prospectively during the treatment period and during 
follow-up (12 wk post-treatment). Anaemia events 
were managed according to the usual practice at each 
hospital. Anaemia was defined as mild or grade 0-1-2 
for haemoglobin values > 8 gr/dL, and as severe or 
grade 3-4 for Hb < 8 gr/dL. Other cytopaenias were 
also classed as mild (grade 0-1-2) or severe (grade 3-4) 
according to the values of neutrophils (neutropaenia 
grade 0-1-2, > 750 μL; grade 3-4 neutropaenia, < 750 
μL) and of platelets (thrombocytopaenia grade 0-1-2, 
> 50000 μL; grade 3-4 thrombocytopaenia, < 50000 
μL). The use of erythropoietin or other growth factors, 
and/or of blood transfusion, was also noted.
Statistical analysis
The baseline and demographic characteristics of 
the study population were analysed descriptively by 
treatment arm (BOC and TVR) and clinical situation (TN 
and TE). The quantitative variables are expressed as 
mean ± SD and the qualitative variables as absolute 
values with percentages. Inter-group comparisons 
for qualitative variables were made using the χ 2 test 
or Fisher’s exact test, and the quantitative variables, 
using Student’s t-test; non-normal distribution 
variables were tested using the Mann-Whitney U 
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Table 1  Group of patients according to hepatitis C virus treatment history  n  (%)
All patients BOC TVR P value Fibrosis Non-F4 F4 P value
(n  = 1057) (100) (n  = 405) (38) (n  = 652) (62) All patients (n  = 423) (44) (n  = 545) (56)
(n = 958) (100)
TN 319 (30) 130 (32) 189 (29) 0.000 294 (30) 129 (31) 165 (30) 0.010
TE 738 (70) 275 (68) 463 (71) 664 (70) 294 (67) 380 (70)
   R 298 (28)   77 (19) 221 (34) 270 (28) 138 (33) 132 (24)
   PR 123 (12)   55 (14)   68 (10) 113 (12)   44 (10)   69 (13)
   NR 260 (25) 119 (29) 141 (22) 238 (25)   86 (20) 152 (28)
   Unknown responders 57 (5) 24 (6) 33 (5) 53 (6) 26 (6) 27 (5)
Bivariate analysis: χ 2 tests. TN: Treatment-naïve; TE: Treatment-experienced; R: Relapsers; PR: Partial responders; NR: Null responders; Unknown 
responders: Treatment-experienced with response unknown.
A
28
45
63
55
82
77
6359
65
52
0.000 NS NS NS 0.00100
80
60
40
20
0
SV
R
w
12
 (
%
) 
IT
T
Total patients Naïve Relapsers Partial 
responders
Null 
responders
BOC                         TVR
63/
141
33/
119
43/
68
30/
55
182/
221
59/
77
120/
189
77/
130
424/
652
212/
405
46
50
64
58
8279
64656764
NS NS NS NS NS100
80
60
40
20
0
SV
R
w
12
 (
%
) 
m
IT
T
Total patients Naïve Relapsers Partial 
responders
Null 
responders
BOC                         TVR
62/
125
32/
70
43/
67
30/
52
182/
221
57/
72
119/
186
73/
112
422/
631
204/
321
B
Figure 2  SVRw12 intention-to-treatment and modified-intention-to-treatment. SVRw12 rates in ITT (n = 1057) (A), and mITT (n = 952) (B) groups. BOC: Boceprevir; 
TVR: Telaprevir; ITT: Intention-to-treatment; mITT: Modified intention-to-treatment; TN: Treatment-naïve patients; R: Relapsers; PR: Partial responder; NR: Null responder.
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Figure 3  SVRw12 according to stage of fibrosis. Response to treatment according to stage of fibrosis (Non-F4 vs F4) in all patients (A), in the group of patients 
treated with BOC (B) and in the group of patients treated with TVR (C). BOC: Boceprevir; TVR: Telaprevir; HCV: Hepatitis C virus.
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following causes of death were recorded: two patients, 
cardiovascular problems; one patient, lung neoplasm 
unrelated to treatment; two patients, severe infection 
(pneumonia and salmonellosis respectively); one 
patient with non-F4 stage, hepatic decompensation; 
four patients with very advanced liver cirrhosis, multi-
organ failure caused by severe anaemia, hepatic 
decompensation, hepatic encephalopathy, infection 
and digestive haemorrhage; one patient, unknown 
cause unrelated to treatment.
The adverse haematologic effects observed are 
shown in Table 5. With respect to neutrophils (n = 
943), 25% of the patients had severe neutropaenia 
(grade 3-4), this being more common in the 
patients given BOC (33% vs 20%, P ≤ 0.0001). 
Thrombocytopaenia occurred in the same proportion in 
patients given BOC and in those given TVR, although it 
was higher in the F4 than in the non-F4 patients (26% 
vs 8%, P ≤ 0.0001). No significant differences were 
observed in the degree of anaemia among the patients 
treated with BOC or TVR; however, the fact that the 
proportion of patients with severe anaemia (grade 3-4) 
was greater in the TVR patients (10% vs 8%, P > 0.05), 
led to more of these patients receiving transfusions 
(P = 0.001) and EPO (P ≤ 0.0001). Severe anaemia 
was also more frequent in the F4 patients than in the 
non-F4 patients (11% vs 7%, P = 0.025).
DISCUSSION
The data presented in this study reflect the experience 
of standard clinical practice, in a cohort of 1057 
patients with CHC genotype 1, treated with BOC or 
TVR in triple therapy. We analyse the effectiveness and 
safety profiles of triple therapy with first-generation PIs 
in combination with PEG-IFN/RBV, in both TN and TE 
patients, most of whom presented an advanced grade 
of fibrosis. The inclusion of patients in one or other of 
the treatment arms was decided by the physician, and 
for this reason more R patients were given TVR than 
BOC, while more NR patients were given BOC than 
TVR. The baseline characteristics were very similar 
among the two groups of patients, although the 
presence of liver fibrosis may have led to different SVR 
rates in the TN and PR groups, to different levels of 
albumin in the R and PR groups, and to different levels 
of GGT in the NR patients. The remaining variables did 
not present significant differences.
The SVR rates obtained were similar to those 
reported in previous clinical trials[19,20]. Thus, the R 
patients presented the highest SVR rates and the NR 
patients, the lowest[21]. The SVR rates were similar 
in all the subgroups of patients, for BOC and TVR by 
ITT and mITT, with the sole exception of the NR group 
by ITT. In a prospective analysis of 511 patients with 
liver cirrhosis, treated previously (the CUPIC study)[12], 
the SVR rates were lower than those obtained in 
our cohort, probably because these patients had a 
more advanced stage of liver disease. However, in 
the CUPIC study the proportion of patients with no 
response to previous treatment was 8% vs 25% in 
our study. Regarding the TN patients treated with BOC 
or TVR, our observed rates of SVR were also lower 
than those observed in another prospective study of 
621 TN patients, in which 266 patients were treated 
with BOC or TVR, obtaining SVR rates of 76.6% and 
71.1% respectively[22]. In our study, the SVR rates 
in the TN patients were closer to those achieved in 
an observational study of a cohort of 835 American 
Veterans patients[23]. The high proportion of F4 patients 
(56%) in our study is comparable to the observations 
obtained from a study of over 1500 TN and TE patients 
with advanced liver fibrosis and treated with TVR[14]. 
Analysis of the rate of SVR in response to treatment, 
according to the degree of fibrosis, showed that 
non-F4 patients responded better than F4 patients, 
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Table 3  Analyses of factors related to sustained virologic response: Univariate and multivariate effectiveness analysis
ITT mITT
Univariate Multivariate Univariate Multivariate
OR 95%CI P  value OR 95%CI P  value OR 95%CI P  value OR 95%CI P  value
Previous response1
   R 2.6   1.8-3.7 0.000 1.8 1.09-3.1 0.022 2.4 1.6-3.5 0.000 1.9   1.1-3.3 0.019
   PR 0.9   0.6-1.3 NS 0.9   0.5-1.7 NS 0.9 0.6-1.3 NS 0.8   0.4-1.6 NS
   NR 0.4   0.2-0.5 0.000 0.6 0.37-0.9 0.330 0.5 0.3-0.7 0.000 0.7 0.39-1.1 NS
IL28B2
   CC 3.6   2.2-5.9 0.000   3.07   1.5-5.9 0.001 3.2 1.9-5.4 0.000 3.0   1.4-6.0 0.002
   CT 1.8   1.2-2.6 0.003 1.6 1.001-2.6 0.049 1.8 1.2-2.8 0.004 1.6   0.9-2.7 NS
Fibrosis3
   Non-F4 2.1   1.6-2.8 0.000 2.0 1.33-3.0 0.001   2.26 1.7-3.04 0.000 2.1   1.4-3.3 0.000
Treatment4
   TVR 1.7   1.3-2.1 0.000 1.5 1.02-2.2 0.038 1.1 0.9-1.5 NS 1.1   0.7-1.7 NS
LogGGT   0.19 0.12-0.3 0.000 0.3 0.18-0.6 0 0.2 0.15-0.23 0.000 0.4   0.2-0.7 0.004
LogViral load 0.8 0.6-1.003 NS 0.7 0.5-0.99 0.048 0.8 0.6-1.003 NS 0.7   0.4-1.1 NS
1TN; 2TT; 3F4; 4BOC. TN: Treatment-naïve patients; R: Relapsers; PR: Partial responders; NR: Null responders; BOC: Boceprevir; ITT: Intention-to-treatment; 
mITT: Modified intention-to-treatment.
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treatments, especially those based on interferon-free 
regimens, will radically change the use of these drugs, 
which currently have a very significant rate of adverse 
effects.
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data about the treatment of HCV, on a broad scale. The effectiveness of first-
generation PIs was generally high, except for null responders (NR) patients. 
Future treatments, especially those based on interferon (IFN)-free regimens, 
will radically change the use of these drugs, which currently have a very 
significant rate of adverse effects.
Innovations and breakthroughs
This study represents a significant contribution to knowledge of the 
effectiveness and safety of the first generation NS3/4A PIs in patients with 
advanced fibrosis in routine clinical practice and contributes to the new 
treatment with inhibitors of second generation NS3/4A and IFN-free treatment.
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Table 5  Haematological adverse events  n  (%)
All patients Boceprevir Telaprevir P  value Non-F4 F4 P value
Neutropaenia n = 943 n = 360 n = 583 n = 369 n = 505
   Grade 0-1-2: 707 (75) 241 (67) 466 (80) 0 289 (78) 370 (73) NS
      > 750 μL
   Grade 3-4: 236 (25) 119 (33) 117 (20) 80 (22) 135 (27)
      ≤ 750 μL
Thrombocytopaenia n = 935 n = 359 n = 576 n = 365 n = 501
   Grade 0-1-2: 0.000
      > 50.000 μL 753 (81) 293 (82) 460 (80) NS 337 (92) 371 (74)
   Grade 3-4:
      ≤ 50.000 μL 182 (20) 66 (18) 116 (20) 28 (8) 130 (26)
Anaemia n = 1036 n = 397 n = 639 n = 411 n = 539
   Grade 0-1-2: 943 (91) 367 (92) 576 (90) NS 384 (93) 481 (89) 0.025
      > 8 g/dL
   Grade 3-4: 93 (9) 30 (8) 63 (10) 27 (7) 58 (11)
      < 8 g/dL
Transfusion n = 1036 n = 397 n = 639 0.001 n = 411 n = 539 NS
150 (15) 39 (10) 111 (17) 49 (12) 85 (16)
EPO n = 1033 n = 396 n = 637 0 n = 410 n = 539 NS
218 (21) 60 (15) 158 (25) 75 (18) 117 (22)
Onset of anaemia 
(≤ 9.5 g/dL)
12 ± 8 15 ± 11 9.5 ± 6.1 0 11.3 ± 7.2 11.5 ± 9 NS
n (%) and χ 2 tests summarise the categorical variables; mean ± SD and Student’s t-test. NS: Not significant.
 COMMENTS
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Applications
This report is the largest real-practice analysis in Spain; it represents a 
nationwide registry with 1057 patients treated with HCV antiviral therapy with 
triple therapy containing 1st generation PIs BOC and TVR. These results could 
be useful to the medical community, especially in those countries were access 
to new direct agents antiviral may be restricted or non-accessible.
Peer-review
This manuscript by Salmerón et al described the effectiveness and safety of PI-
based triple therapy in real-world cohorts including large numbers of patients 
with advanced liver disease (56% of patients with cirrhosis). The effectiveness 
of first-generation PIs was generally high, except for NR patients, and according 
to the degree of fibrosis, the non-F4 patients responded better than F4 patients.
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